Erste Group Bank Issues Positive Estimate for Amgen Earnings

Amgen Inc. (NASDAQ:AMGN) – Erste Group Bank lifted their FY2027 earnings estimates for Amgen in a research report issued to clients and investors on Thursday, August 27th. Erste Group Bank analyst H. Engel now expects that the medical research company will earn $24.43 per share for the year, up from their previous forecast of $23.50. Erste Group Bank has a “Hold” rating on the stock. The consensus estimate for Amgen’s current full-year earnings is $22.97 per share.

Other equities research analysts also recently issued research reports about the company. Royal Bank Of Canada increased their price objective on Amgen from $370.00 to $400.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Canaccord Genuity Group lifted their price target on Amgen from $366.00 to $384.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. Bank of America upped their price objective on shares of Amgen from $312.00 to $317.00 and gave the company an “underperform” rating in a research note on Wednesday, August 5th. Truist Financial upped their target price on Amgen from $340.00 to $362.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. Finally, Sanford C. Bernstein increased their price target on shares of Amgen from $335.00 to $345.00 and gave the stock a “market perform” rating in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $380.43.

Amgen Stock Performance

AMGN opened at $429.88 on Tuesday. The business has a 50 day moving average price of $390.35 and a two-hundred day moving average price of $365.09. Amgen has a 1-year low of $269.77 and a 1-year high of $447.03. The company has a market capitalization of $232.41 billion, a price-to-earnings ratio of 26.72, a price-to-earnings-growth ratio of 3.12 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. During the same period last year, the firm posted $6.02 EPS. Amgen’s quarterly revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s dividend payout ratio (DPR) is 62.65%.

Insider Activity

In related news, SVP Rachna Khosla sold 1,252 shares of the stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the transaction, the senior vice president directly owned 6,404 shares in the company, valued at $2,666,817.72. This represents a 16.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares in the company, valued at $2,951,854.40. The trade was a 28.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 6,222 shares of company stock valued at $2,540,926 over the last three months. Company insiders own 0.85% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Rational Advisors Inc. increased its stake in Amgen by 13.7% in the 2nd quarter. Rational Advisors Inc. now owns 199 shares of the medical research company’s stock valued at $72,000 after buying an additional 24 shares during the last quarter. Beacon Financial Advisory LLC increased its position in Amgen by 2.0% during the second quarter. Beacon Financial Advisory LLC now owns 1,274 shares of the medical research company’s stock worth $461,000 after buying an additional 25 shares during the last quarter. Legacy Financial Advisors Inc. raised its stake in Amgen by 0.8% in the 2nd quarter. Legacy Financial Advisors Inc. now owns 3,407 shares of the medical research company’s stock valued at $1,234,000 after acquiring an additional 26 shares during the period. Roman Butler Fullerton & Co. raised its position in shares of Amgen by 1.4% in the second quarter. Roman Butler Fullerton & Co. now owns 1,956 shares of the medical research company’s stock valued at $705,000 after purchasing an additional 27 shares during the period. Finally, High Note Wealth LLC lifted its position in Amgen by 5.8% during the fourth quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock worth $166,000 after acquiring an additional 28 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Repatha demonstrated a meaningful mortality benefit. Amgen reported that Repatha reduced the risk of death by 20% in more than 12,000 high-risk adults who had not previously experienced a heart attack or stroke. The findings came from a prespecified analysis of the Phase 3 VESALIUS-CV trial presented at the 2026 European Society of Cardiology Congress. The result could support broader use of Repatha beyond cholesterol reduction and strengthen one of Amgen’s key revenue drivers. Amgen Repatha clinical results
• Positive Sentiment: Analyst sentiment and performance comparisons remain supportive. Commentary says AMGN has outperformed the broader market over the past year, with analysts moderately bullish on its future prospects. Erste Group Bank also issued a positive forecast for Amgen’s earnings, adding to the favorable outlook. Amgen stock performance comparison
• Neutral Sentiment: Industry growth could provide a secondary opportunity. A new report identifies Amgen among companies participating in the expanding palmoplantar pustulosis market, driven by increased diagnosis and demand for biologic treatments. However, the report does not identify a specific Amgen product or provide a material revenue forecast, so the immediate stock impact is likely limited. Palmoplantar pustulosis market report

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.